slide1 l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
“ Barriers to enrolling patients with ovarian cancer in clinical trials in the state of Oregon ” Fabio Cappuccini, M PowerPoint Presentation
Download Presentation
“ Barriers to enrolling patients with ovarian cancer in clinical trials in the state of Oregon ” Fabio Cappuccini, M

Loading in 2 Seconds...

play fullscreen
1 / 20

“ Barriers to enrolling patients with ovarian cancer in clinical trials in the state of Oregon ” Fabio Cappuccini, M - PowerPoint PPT Presentation


  • 127 Views
  • Uploaded on

“ Barriers to enrolling patients with ovarian cancer in clinical trials in the state of Oregon ” Fabio Cappuccini, MD, Analene Pentopoulos, MD Gynecologic Oncology Oregon Health & Science University Center for Women’s Health March 25, 2006. Enrollment in Clinical Trials.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about '“ Barriers to enrolling patients with ovarian cancer in clinical trials in the state of Oregon ” Fabio Cappuccini, M' - eris


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

“Barriers to enrolling patients with ovarian cancer in clinical trials in the state of Oregon”

Fabio Cappuccini, MD, Analene Pentopoulos, MD

Gynecologic Oncology

Oregon Health & Science University

Center for Women’s Health

March 25, 2006

enrollment in clinical trials
Enrollment in Clinical Trials

In the past decade, clinical trial enrollment rates ranged from 3% for breast cancer to 14% for all cancer patients.

Greater than 70% of children are enrolled, but only 1.5% of adult patients ≥ 50.2

1. Lara PN, Higdon R, Lim N, Kwan K, et al. Prospective evaluation on cancer clinical trial accrual patterns: Identifying potential barriers to enrollment. Journal of Clinical Oncology. 19(6) 2001: 1728-1733.

2.Kornblith AB, Kemeny M, Peterson BL et al. Survey of oncologists’ perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials Cancer 2002;95:989-96.

public attitudes
Public Attitudes
  • Phone survey of 1000 American adults showed that 32% are very willing to participate in clinical trials and an additional 38% were inclined to participate but had reservations.1
  • 86% of respondents felt that women should be asked to participate in clinical trials, with 33% stating that they would accept participation.2

1. Comis RL et al. Public attitudez toward participation in cancer clinical trials. J Clin Oncol 2003;21:830-35.

2. Ellis PM et al. Randomized clinical trials in oncology: Understanding and attitudes predict willingness to participate. J Clin Oncol 2001;19:3554-61.

role of the physician
Role of the physician
  • Women whose primary physician advised them to enroll were 13x more likely to participate than women whose physician advised them not to participate.1
  • Study looked at enrollment of patients into GOG studies at one institution. Found that more senior faculty and those that were PI for studies were more likely to offer patients enrollment and their patients were more likely to accept enrollment.2

Kinney AY et al. Ther effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial. Prev Med 1998;27:713-9

Mannel RS et al. Impact on individual physicians on enrollment of patients into clinical trials. Am J Clin Onco2003;26:171-3

barriers to enrollment in clinical trials
Barriers to Enrollment in Clinical Trials
  • Type of insurance coverage
  • Age
  • Race
  • Sex
  • Socioeconomic status
  • Educational level
  • Type of cancer
  • Patient understanding of protocol
  • Physician’s explanation of protocol
legislative measures
Legislative Measures
  • National Institutes of Health Revitalization Act of 1993
  • Creation of a Minority Community Clinical Oncology Program by the NCI
  • Focused initiatives with the Center of Disease Control and Prevention and Academic Medical Center
  • Increase in NCI budget from $2 billion in 1993 to $4 billion in 2002
objectives
Objectives
  • To identify the barriers to enrollment onto ovarian cancer clinical trials, relying on direct interviews with the patient
  • Using the State of Oregon as a model
methods
Methods
  • Patients diagnosed with ovarian cancer in the state of Oregon were indentified by the Oregon Cancer Registry
  • Survey covered patient's demographic background, treatment for ovarian cancer, knowledge about and participation in clinical trials
  • A second survey was sent to all non-respondents after 3 weeks
results
Results

Between 1999 and 2003, there were 1262 cases of ovarian cancer reported to OSCaR

637 – patients are alive

560 – surveys initially mailed

305 -- surveys have been returned

43 – declined to answer

262 – available for analysis

results demographics
Results - Demographics
  • Mean age 60.0 yrs
  • Mean age at dx 55.9 yrs
  • English speaking 97.3

Education

Race

results continued
Results continued

99.3% of respondents underwent surgery

Chemotherapy was discussed with 89.6% of respondents

results continued12
Results continued

Of the women offered a clinical trial, 53% accepted enrollment

factors that influence enrollment
Factors That Influence Enrollment

Desire to help future patients 18/19

Desire to advance research 17/19

Recommendation of MD 15/19

Recommendation of family/friend 7/19

Hope for better treatment 10/19

Trial was well explained 16/19

conclusions
Conclusions

Most women in Oregon with ovarian cancer do not know about clinical trials.

Only a small percentage of women with ovarian cancer are offered enrollment in clinical trials by their physician limiting the number of women available for enrollment.

patient quotes
Patient Quotes

“ I have always asked if there was a trial I would benefit. The answer was no…I feel it is the responsibility of the oncologist to determine and let you know what’s out there instead of the patient asking if there is anything out there that would be of help”

“ The clinical trials I am on or did consider were the result of research my husband did online…it seems the prospect of clinical trials is the responsibility of the patient”

patient quotes16
Patient Quotes

“ It is my hope that clinical studies will begin to include older people – people in their 80’s and beyond. We would like to have the option of living longer too, if given the chance”

“ In spite of a poster…saying to ask about clinical trials, I always felt that there was a pervasive strong underlying reluctance to explore the possibility”

differences

Offered

Not offered

Mean age

55.1

56

City of Diagnosis (Portland Metro)

58.3%

41.4%

Education (high school or some college)

65%

59%

Differences
differences between accept decline groups

Accept

Decline

Mean age

56.9

55.9

City of Dx (Portland Metro)

63.2%

53.3%

Education

(High school or some college)

53%

64.6%

Differences Between Accept/decline Groups